{"id":"triptorelin-embonate","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Hot flashes"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to GnRH receptors in the pituitary gland, triptorelin embonate triggers a cascade of downstream effects that ultimately lead to the suppression of gonadotropin secretion, resulting in decreased levels of sex hormones such as testosterone and estrogen. This mechanism is exploited to treat hormone-sensitive cancers and other conditions.","oneSentence":"Triptorelin Embonate is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:35.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT07319429","phase":"PHASE2, PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Endometrial Cancer, Fertility","enrollment":260},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT07254429","phase":"PHASE2","title":"COMPASS - COpenhagen MenoPAuSe Study","status":"RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-10-02","conditions":"Menopausal Osteoporosis, Bone Markers","enrollment":192},{"nctId":"NCT06129539","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Debiopharm International SA","startDate":"2024-07-31","conditions":"Central Precocious Puberty","enrollment":56},{"nctId":"NCT05377684","phase":"","title":"Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2022-06-09","conditions":"Early-stage Breast Cancer","enrollment":450},{"nctId":"NCT06134479","phase":"PHASE3","title":"Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.","status":"COMPLETED","sponsor":"Fundación Santiago Dexeus Font","startDate":"2023-12-12","conditions":"Fertility","enrollment":194},{"nctId":"NCT06513962","phase":"PHASE3","title":"Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-27","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT05896566","phase":"PHASE2","title":"A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2024-01-23","conditions":"Breast Cancer","enrollment":231},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":"Breast Cancer","enrollment":181},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":"Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma","enrollment":3066},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT05701007","phase":"","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-13","conditions":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":1083},{"nctId":"NCT06913075","phase":"NA","title":"FET in Adenomyosis","status":"NOT_YET_RECRUITING","sponsor":"Indira IVF Hospital Pvt Ltd","startDate":"2026-06-25","conditions":"Adenomyosis","enrollment":700},{"nctId":"NCT05498272","phase":"PHASE2","title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","status":"RECRUITING","sponsor":"Rana McKay, MD","startDate":"2023-02-01","conditions":"Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation","enrollment":32},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT07242534","phase":"PHASE4","title":"Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","status":"RECRUITING","sponsor":"Fundacion Dexeus","startDate":"2026-01-19","conditions":"Infertility, Obesity","enrollment":62},{"nctId":"NCT04356664","phase":"PHASE2, PHASE3","title":"Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2021-03-18","conditions":"Endometriosis, Adenomyosis, Infertility, Female","enrollment":180},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":"Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT07187947","phase":"","title":"Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-18","conditions":"Gender Incongruence, Cardiovascular (CV) Risk, Cardiovascular Disease Risk Factor","enrollment":500},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT05590793","phase":"PHASE3","title":"Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-11-17","conditions":"Advanced Prostate Cancer, Metastatic Prostate Cancer, Locally Advanced Prostate Cancer","enrollment":195},{"nctId":"NCT01492972","phase":"PHASE3","title":"Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT06150703","phase":"PHASE3","title":"Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-27","conditions":"In Vitro Fertilization, ICSI Intracytoplasmic Spermatozoid Injection","enrollment":652},{"nctId":"NCT05625087","phase":"PHASE2","title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2023-10-19","conditions":"Breast Cancer Stage IV","enrollment":162},{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":"Infertility, Female, Luteinizing Hormone (LH)","enrollment":590},{"nctId":"NCT04181203","phase":"PHASE3","title":"Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-01-09","conditions":"Prostate Cancer","enrollment":490},{"nctId":"NCT05458856","phase":"PHASE3","title":"Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-08-30","conditions":"Prostate Cancer","enrollment":147},{"nctId":"NCT07076719","phase":"","title":"Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-10-01","conditions":"to Evaluate the Feasibility and Accuracy of Using cfDNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for PGD","enrollment":20},{"nctId":"NCT00963417","phase":"NA","title":"Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2009-08-03","conditions":"Breast Cancer, Osteoporosis","enrollment":119},{"nctId":"NCT00667069","phase":"PHASE3","title":"Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2008-04-07","conditions":"Prostate Cancer","enrollment":424},{"nctId":"NCT01673984","phase":"PHASE4","title":"GP Extended Action Triptorelin","status":"TERMINATED","sponsor":"Ipsen","startDate":"2012-08","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT05982093","phase":"PHASE2","title":"Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2023-02-03","conditions":"Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor","enrollment":48},{"nctId":"NCT02278185","phase":"PHASE2","title":"Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-11-11","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer","enrollment":19},{"nctId":"NCT00567580","phase":"PHASE3","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":1792},{"nctId":"NCT06225284","phase":"PHASE2","title":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-08-22","conditions":"Triple Negative Breast Cancer, Premenopausal Breast Cancer","enrollment":124},{"nctId":"NCT06795178","phase":"PHASE3","title":"Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer","status":"WITHDRAWN","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06795191","phase":"PHASE3","title":"Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer","status":"WITHDRAWN","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02346253","phase":"NA","title":"High-Dose Brachytherapy in Treating Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2015-01-13","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":146},{"nctId":"NCT03944434","phase":"PHASE2","title":"FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT06763926","phase":"PHASE4","title":"Intranasal Nafarelin For Triggering Oocyte Maturation","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Dexeus","startDate":"2025-03-15","conditions":"Fertility Disorders","enrollment":134},{"nctId":"NCT05029622","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-08-10","conditions":"Central Precocious Puberty","enrollment":66},{"nctId":"NCT05286554","phase":"PHASE4","title":"Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-03-17","conditions":"Female Infertility","enrollment":75},{"nctId":"NCT02588404","phase":"","title":"The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT04992026","phase":"PHASE2","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-01-01","conditions":"Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone","enrollment":130},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT06525155","phase":"PHASE3","title":"Effect GnRH Agonist Administration in Endometriosis Cyst Patients","status":"RECRUITING","sponsor":"Rumah Sakit Pusat Angkatan Darat Gatot Soebroto","startDate":"2024-01-02","conditions":"Endometriosis","enrollment":32},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT06691815","phase":"NA","title":"Triptorelin for Early Diagnosis of Hypogonadotrophic Hypogonadism","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital de Niños R. Gutierrez de Buenos Aires","startDate":"2022-08-01","conditions":"Pubertal Delay, Hypogonadism, Hypogonadotropic, Constitutional Delay in Growth and Puberty (CDGP)","enrollment":48},{"nctId":"NCT01969578","phase":"PHASE2","title":"Androgen Deprivation Therapy in Advanced Salivary Gland Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2015-09-24","conditions":"Salivary Gland Cancer","enrollment":149},{"nctId":"NCT05759273","phase":"","title":"A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy","status":"COMPLETED","sponsor":"Ipsen","startDate":"2023-04-24","conditions":"Prostate Cancer","enrollment":167},{"nctId":"NCT00702520","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04-01","conditions":"Pregnancy, Neonates","enrollment":15},{"nctId":"NCT06581679","phase":"NA","title":"Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2023-12-15","conditions":"Adenomyosis","enrollment":184},{"nctId":"NCT04736602","phase":"PHASE3","title":"Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-03-27","conditions":"Central Precocious Puberty","enrollment":32},{"nctId":"NCT06396390","phase":"PHASE4","title":"Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nesta Clinic","startDate":"2024-08-01","conditions":"IVF, Fertility Issues, Infertility","enrollment":152},{"nctId":"NCT02400801","phase":"NA","title":"Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-06","conditions":"Endometriosis, Infertility","enrollment":166},{"nctId":"NCT06487143","phase":"PHASE4","title":"Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07-01","conditions":"Central Precocious Puberty","enrollment":134},{"nctId":"NCT06481696","phase":"NA","title":"Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility","status":"RECRUITING","sponsor":"Andros Day Surgery Clinic","startDate":"2024-06-01","conditions":"Unexplained Infertility","enrollment":90},{"nctId":"NCT06473259","phase":"","title":"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","status":"RECRUITING","sponsor":"Santa Chiara Hospital","startDate":"2016-12-16","conditions":"Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Tumor","enrollment":3000},{"nctId":"NCT02418572","phase":"PHASE3","title":"Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial","status":"TERMINATED","sponsor":"Fundacion Dexeus","startDate":"2015-04","conditions":"Infertility, Poor Ovarian Response","enrollment":290},{"nctId":"NCT05802303","phase":"NA","title":"Estrogen (Gel)Transdermal vs Oral Estrogen for Endometrial Preparation","status":"TERMINATED","sponsor":"Indira IVF Hospital Pvt Ltd","startDate":"2023-07-25","conditions":"Frozen Embryo Transfer, Infertility, Female","enrollment":172},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":960},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT05851547","phase":"PHASE2","title":"Dose Escalation For INtraprostatic LEsions","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-11-23","conditions":"Prostatic Neoplasms","enrollment":54},{"nctId":"NCT06191809","phase":"NA","title":"Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization","status":"UNKNOWN","sponsor":"Hanoi Medical University","startDate":"2023-02-14","conditions":"IVF","enrollment":200},{"nctId":"NCT04242017","phase":"PHASE2, PHASE3","title":"Long-term Better Than Short-term ADT With Salvage RT","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-07-07","conditions":"Prostate Cancer","enrollment":394},{"nctId":"NCT05567731","phase":"NA","title":"Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-15","conditions":"Intracytoplasmic Sperm Injection, GnRH Agonist, Infertility","enrollment":30},{"nctId":"NCT06146413","phase":"PHASE2","title":"Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger","status":"UNKNOWN","sponsor":"Bedaya Hospital","startDate":"2023-12-30","conditions":"Infertility","enrollment":150},{"nctId":"NCT05781217","phase":"PHASE3","title":"Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-03-14","conditions":"Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence","enrollment":534},{"nctId":"NCT02330770","phase":"PHASE4","title":"Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-06-06","conditions":"Infertility","enrollment":225},{"nctId":"NCT02312076","phase":"PHASE4","title":"GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-09-09","conditions":"Infertility","enrollment":200},{"nctId":"NCT02312089","phase":"PHASE4","title":"GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-08-07","conditions":"Infertility","enrollment":200},{"nctId":"NCT05328258","phase":"PHASE3","title":"Use of GnRHa During Chemotherapy for Fertility Protection","status":"RECRUITING","sponsor":"Kenny Rodriguez-Wallberg","startDate":"2023-03-31","conditions":"Breast Cancer Female, Acute Leukemia, Lymphoma","enrollment":500},{"nctId":"NCT04724486","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"ANAEMIA"},{"count":7,"reaction":"FATIGUE"},{"count":7,"reaction":"WEIGHT DECREASED"},{"count":5,"reaction":"ACUTE KIDNEY INJURY"},{"count":5,"reaction":"DYSPNOEA"},{"count":4,"reaction":"DIARRHOEA"},{"count":4,"reaction":"MUSCLE ATROPHY"},{"count":4,"reaction":"NEUTROPENIA"},{"count":4,"reaction":"PAIN IN EXTREMITY"},{"count":4,"reaction":"PALLOR"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pamorelin"],"phase":"phase_3","status":"active","brandName":"Triptorelin Embonate","genericName":"Triptorelin Embonate","companyName":"Marco Lorenzo Bonu","companyId":"marco-lorenzo-bonu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptorelin Embonate is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist. Used for Prostate cancer, Breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}